1.
Damschroder LJ, Hagedorn HJ. A guiding framework and approach for implementation research
in substance use disorders treatment. Psychol Addict Behav. 2011;25(2):194–205.
2.
Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for
Implementation Research: Conceptual Distinctions, Measurement Challenges, and Research
Agenda. Adm Policy Ment Health Ment Health Serv Res. 2011 Mar;38(2):65–76.
4.
Saldana L, Chamberlain P, Bradford WD, Campbell M, Landsverk J. The cost of implementing
new strategies (COINS): A method for mapping implementation resources using the stages
of implementation completion. Child Youth Serv Rev. 2014 Apr;39:177–82.
5.
Ritzwoller DP, Sukhanova A, Gaglio B, Glasgow RE. Costing Behavioral Interventions:
A Practical Guide to Enhance Translation. Ann Behav Med. 2009 Apr;37(2):218–27.
6.
Smith JS, Melendy A, Rana RK, Pimenta JM. Age-Specific Prevalence of Infection with
Human Papillomavirus in Females: A Global Review. J Adolesc Health. 2008 Oct;43(4):S5.e1-S5.e62.
7.
Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection.
Gynecol Oncol. 2007 Nov;107(2):S6–13.
9.
Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide
burden of cervical cancer in 2008. Ann Oncol. 2011 Dec 1;22(12):2675–86.
10.
Singh GK, Azuine RE, Siahpush M. Global inequalities in cervical cancer incidence
and mortality are linked to deprivation, low socioeconomic status, and human development.
Int J MCH AIDS. 2012;1(1):17.
11.
Bruni L, Barrinuevo-Rosas L, Serrano B, Brotons M, Cosano R, Munoz J. Human Papillomavirus
and Related Diseases in the world:Summary report 2016. ICO Information Center on HPV
and Cancer; 2016.
12.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence
and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan
2012. Int J Cancer. 2015 Mar 1;136(5):E359–86.
13.
Naucler P, Mabota da Costa F, da Costa JL, Ljungberg O, Bugalho A, Dillner J. Human
papillomavirus type-specific risk of cervical cancer in a population with high human
immunodeficiency virus prevalence: case-control study. J Gen Virol. 2011 Dec 1;92(12):2784–91.
14.
Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus
vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014 Jul;2(7):e406–14.
15.
Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level
impact and herd effects following human papillomavirus vaccination programmes: a systematic
review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–580.
16.
Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness
of less than three doses of quadrivalent human papillomavirus vaccine against cervical
intraepithelial neoplasia when administered using a standard dose spacing schedule:
Observational cohort of young women in Australia. Papillomavirus Res. 2015 Dec;1:59–73.
17.
Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early Impact of Human Papillomavirus
Vaccination on Cervical Neoplasia--Nationwide Follow-up of Young Danish Women. JNCI
J Natl Cancer Inst. 2014 Mar 26;106(3):djt460–djt460.
18.
WHO. Comprehensive cervical cancer control: A guide to essential practice. Geneva,
Switzerland; 2006 p. 272. (Integrating health care for sexual and reproductive health
and chronic diseasea).
19.
Castro A, Cinà M, Helmer-Smith M, Vlček C, Oghor C, Cazabon D. A case study of Gavi’S
human papillomavirus vaccine support programme. J Health Spec. 2017;5(1):2.
20.
Howard N, Mounier-Jack S, Gallagher KE, Kabakama S, Griffiths UK, Feletto M, et al.
The value of demonstration projects for new interventions: The case of human papillomavirus
vaccine introduction in low- and middle-income countries. Hum Vaccines Immunother.
2016 Sep;12(9):2475–7.
21.
Hanson C, Eckert L, Bloem P, Cernuschi T. Gavi HPV Programs: Application to Implementation.
Vaccines. 2015 May 20;3(2):408–19.
22.
Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: From promise
to practice. PLOS Med. 2017 Jun 27;14(6):e1002325.
23.
LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress
in HPV vaccination in low- and lower-middle-income countries. Int J Gynecol Obstet.
2017 Jul;138:7–14.
24.
Gavi team. Gavi HPV Programme. Workshop in Senegal; 2018 Feb 1; Dakar, Senegal.
25.
Howard N, Gallagher KE, Mounier-Jack S, Burchett HED, Kabakama S, LaMontagne DS, et
al. What works for human papillomavirus vaccine introduction in low and middle-income
countries? Papillomavirus Res. 2017 Dec;4:22–5.
26.
Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of Introducing and Delivering
HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction
Grant Support to Countries. Metcalfe JZ, editor. PLoS ONE. 2014 Jun 26;9(6):e101114.
27.
Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost effectiveness
in health and medicine. Second edition. Oxford ; New York: Oxford University Press;
2017. 496 p.
28.
Bergmo TS. How to Measure Costs and Benefits of eHealth Interventions: An Overview
of Methods and Frameworks. J Med Internet Res. 2015 Nov 9;17(11):e254.
29.
Gray A, editor. Applied methods of cost-effectiveness analysis in health care. Oxford ;
New York: Oxford University Press; 2011. 313 p. (Handbooks in health economic evaluation
series).
30.
Organization WH. Guidelines for estimating costs of introducing new vaccines into
the national immunization system. 2002;
31.
World Health Organization. Scaling-up HPV vaccine introduction. WHO; 2016.
32.
Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, et al. A case study using
the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the
WHO Cervical Cancer Prevention and Control Costing Tool. BMC Med. 2012;10(1):136.
33.
Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, et al. Experiences
of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration
projects. Grce M, editor. PLOS ONE. 2017 Oct 10;12(10):e0182663.
34.
Meltzer MI. Introduction to health economics for physicians. The Lancet. 2001;358(9286):993–998.
35.
Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G. Methods for the Economic
Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015. 464 p.
36.
Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model Parameter
Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Good Research
Practices Task Force Working Group–6. Med Decis Making. 2012 Sep;32(5):722–32.
37.
Mozambique Instituto Nacional de Estatística (National Statistics Institute). Mozambique
Census 2007. Mozambique Instituto Nacional de Estatística; 2008.
39.
R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
Austria: The R Foundation; 2019. Available from: URL http://www.R-project.org/
40.
Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. Standards for QUality
Improvement Reporting Excellence 2.0: revised publication guidelines from a detailed
consensus process. J Surg Res. 2016 Feb;200(2):676–82.
41.
Dieleman JL, Campbell M, Chapin A, Eldrenkamp E, Fan VY, Haakenstad A, et al. Future
and potential spending on health 2015–40: development assistance for health, and government,
prepaid private, and out-of-pocket health spending in 184 countries. The Lancet. 2017
May;389(10083):2005–30.
42.
National Immunization Program. Mozambique- MULTI-Year Plan - 2014-2018. Mozambique
Ministry of Health; 2013.
43.
Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C, Kayonga C, et al. A cost comparison
of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines
in Rwanda. Vaccine. 2015 Dec;33(51):7357–63.
44.
Clendinen C, Zhang Y, Warburton RN, Light DW. Manufacturing costs of HPV vaccines
for developing countries. Vaccine. 2016 Nov;34(48):5984–9.
45.
Agosti JM, Goldie SJ. Introducing HPV Vaccine in Developing Countries — Key Challenges
and Issues. N Engl J Med. 2007 May 10;356(19):1908–10.
46.
Brenzel L. What have we learned on costs and financing of routine immunization from
the comprehensive multi-year plans in GAVI eligible countries? Vaccine. 2015 May;33:A93–8.
47.
Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity
and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls
in India: a multicentre prospective cohort study. Lancet Oncol. 2016 Jan;17(1):67–77.
48.
Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder
S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine:
combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet
Oncol. 2015 Jul;16(7):775–86.
49.
Kabakama S, Gallagher KE, Howard N, Mounier-Jack S, Burchett HED, Griffiths UK, et
al. Social mobilisation, consent and acceptability: a review of human papillomavirus
vaccination procedures in low and middle-income countries. BMC Public Health [Internet].
2016 Dec [cited 2018 Mar 25];16(1). Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-3517-8